Skip to Content

Ahmed Kaseb, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 426
Houston, TX 77030
Room Number: FC10.3064
Phone: 713-792-2828
Fax: 713-563-0541

Education & Training

Degree-Granting Education

1996 Cairo University School of Medicine, Cairo, Egypt, MD, Medicine

Postgraduate Training

7/2005-6/2007 Medical Oncology Fellow, Internal Medicine, Henry Ford Hospital, Detroit, MI
7/2004-6/2005 Internal Medicine Staff Physician, Internal Medicine, Henry Ford Hospital, Detroit, MI
7/2001-6/2004 Internal Medicine Residency, Internal Medicine, Wayne State University/Detroit Medical Center, Sanai-Grace Hospital, Detroit, MI
9/1999-6/2001 Research Fellowship, Pediatrics and Human Genetics, University of Michigan, Ann Arbor, MI
12/1998-6/1999 Externship, Internal Medicine, Michigan State University, East Lansing, MI
3/1997-2/1998 Clinical Internship, Medicine, Cairo University Hospitals, Cairo, Egypt

Board Certifications

2007 American Board of Medical Oncology
2004 American Board of Internal Medicine


Administrative Appointments/Responsibilities

Editor-in-Chief, Journal of Hepatocellular Carcinoma, Princeton, NJ, 12/2013-present
Founder, Black Seed Group, Houston, TX, 2009-present
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present

Other Appointments/Responsibilities

Founder, Director, Hepatocellular Carcinoma Interdisciplinary Research Group (HIRG), Houston, TX, 5/2009-present

Honors and Awards

2006 ASCO Foundation Merit Award, American Society of Clinical Oncology
2006 Basic Research Presentation Merit Award, 13th Annual Research Forum of Henry Ford Health System
2005 ACP Merit Award, American College of Physicians
2004 ACP Merit Award, American College of Physicians
2004 Best Ambulatory Resident Award, Sinai-Grace Hospital/Wayne State University
1990 The Egyptian Government Award, Egypt

Professional Memberships

American Association for the Study of Liver Disease (AASLD)
Member, 2008-present
American Association of Cancer Research (AACR)
Member, 2008-present
American College of Physicians (ACP)
Member, 2008-present
American Society of Clinical Oncology (ASCO)
Member, 2005-present
Egyptian Medical Syndicate
Member, 1998-present
International Liver Cancer Association (ILCA)
Member, 2008-present
International Society of Gastrointestinal Oncology (ISGIO), Melville, NY
Member, 2008-present
SWOG (Southwest Oncology Group)
Member-Gastrointestinal Committee, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging 39(5):1070-87, 10/2014. e-Pub 4/2014. PMID: 24695938.
2. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 5/2014. e-Pub 5/2014. PMCID: PMC4085880.
3. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget 5(10):3012-22, 5/2014. PMCID: PMC4102787.
4. Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, Hassan MM. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology 86(2):63-71, 2014. e-Pub 1/2014. PMID: 24401634.
5. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surg Clin North Am 93(6):1423-50, 12/2013. PMID: 24206860.
6. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol 3(4):344-8, Oct-Dec, 10/2013. e-Pub 12/2012. PMID: 24674408.
7. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma. Oncology 85(4). e-Pub 9/2013. PMID: 24051705.
8. Kaseb AO. Beyond the Basics: The Differential Effects of Demographics and Hepatitis Status on Treatment Outcome in Hepatocellular Carcinoma. Oncology 85(1). e-Pub 7/2013. PMID: 23838536.
9. Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 119(18). e-Pub 7/2013. PMID: 23821538.
10. Frenette CT, Boktour M, Burroughs SG, Kaseb A, Aloia TA, Galati J, Gaber AO, Monsour H, Ghobrial RM. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int 26(7):734-9, 7/2013. e-Pub 5/2013. PMID: 23701126.
11. Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol 5(6):332-5, 6/2013. PMCID: PMC3692975.
12. Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol Carcinog. e-Pub 6/2013. PMID: 23776098.
13. Shindoh J, Kaseb A, Vauthey JN. Surgical Strategy for Liver Cancers in the Era of Effective Chemotherapy. Liver Cancer 2(1):47-54, 1/2013. PMCID: PMC3747536.
14. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials. Oncotarget 4(1):153-162, 1/2013. e-Pub 1/27/2013. PMCID: PMC3702215.
15. Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, Shousha HI, Barakat AB, El-Desouky ED, Zayed NA, Ahmed OS, El-Din Youssef AS, Kaseb AO, Abd El-Aziz AO, Bahnassy AA. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev 14(11):6721-6, 2013. PMID: 24377595.
16. Kaseb AO, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res 190:247-59, 2013. PMID: 22941025.
17. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of Bevacizumab plus Erlotinib for Advanced Hepatocellular Carcinoma and Predictors of Outcome: Final Results of a Phase II Trial. Oncology 82(2):67-74, 2012. e-Pub 2/7/2012. PMID: 22327795.
18. Mahale P, Kaseb A, Davila M, Torres HA. The Effect of Transcatheter Arterial Chemoembolization on Hepatitis C viremia. Oncologist 17(9):e21-3, 2012. PMCID: PMC3448418.
19. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 29(29):3892-9, 10/10/2011. e-Pub 9/12/2011. PMCID: PMC3189091.
20. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: Improved Stratification of Advanced Hepatocellular Carcinoma Patients by Integrating Plasma IGF-1 into CLIP Score. Oncology 80(5-6). e-Pub 8/3/2011. PMID: 21822028.
21. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs 29(4):694-9, 8/2011. e-Pub 1/27/2010. PMID: 20107864.
22. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol. e-Pub 7/27/2011. PMID: 21793641.
23. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. e-Pub 12/14/2010. PMCID: PMC3066286.
24. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8):1938-46, 4/15/2010. PMID: 20166205.
25. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 115(21):4895-906, 2009, 11/2009. PMID: 19637355.
26. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69(13):5575-83, 7/1/2009. e-Pub 6/23/2009. PMID: 19549912.
27. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49(5):1563-70, 5/2009. PMID: 19399911.
28. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 145(4):399-405, 4/2009. PMID: 19303988.
29. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27(6):843-50, 2/20/2009. e-Pub 1/12/2009. PMID: 19139433.
30. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 50(2):334-41, 2/2009. e-Pub 10/16/2008. PMCID: PMC2658718.
31. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer 123(8):1883-91, 10/15/2008. PMCID: PMC2673571.
32. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res 67(16):7782-8, 8/15/2007. PMID: 17699783.
33. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A 104(7):2343-8, 2/13/2007. e-Pub 2/5/2007. PMCID: PMC1892964.
34. Yang H, Yang K, Khafagi A, Tang Y, Carey TE, Opipari AW, Lieberman R, Oeth PA, Lancaster W, Klinger HP, Kaseb AO, Metwally A, Khaled H, Kurnit DM. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A 102(21):7683-8, 5/2005. PMCID: PMC1140403.
35. Kaseb A, Xiao L, Hassan MM, Abbruzzese JL, Cheung S, Mohamed H, Vierling J, Jalal P, Lee J-S, Wallace MJ, Vauthey J-N, Aloia TA, Curley SA, Rashid A, Morris J. Development and Validation of a modified Child-Turcotte-Pugh score to predict survival in patients with hepatocellular carcinoma. J Clin Oncol. Submitted.


1. Wilson SR, Greig P, Kaseb AO. Pretreatment assessment of hepatocellular cancer: expert consensus conference. HPB (Oxford) 12(5):300-1, 6/2010. PMCID: PMC2951815.

Book Chapters

1. Kaseb A, Thomas M. The Future: Combination Systemic Therapy for Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Ed(s) McMasters K, Vauthey JN. Humana Press. In Press.
2. Hassan M, Kaseb A. Epidemiology and Pathogenesis of Hepatocellular Carcinoma. In: Hepatocellular Carcinoma: A Multidisciplinary Approach. Ed(s) K McMasters, JN Vauthey. Springer, 1-19, 2010. ISBN: 978-1-60327-521-7.
3. Kaseb A, Thomas M, Curley S. Gall Bladder and Bile Duct Cancer. In: Holland-Frei Cancer Medicine, 8. Ed(s) Kufe DW, Frei E, Holland JF, Weichsebaum RR, Pollock RE, Bast RC, Hong WK, Hait WN. People's Medical Publishing House-USA: Shelton, CT, Part Five, Section 27; 87, 2009. ISBN: 1-60795-014-6.
4. Kaseb A, Selim Abdel-Hafez. Kalonji (Thymoquinone). In: Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine. Ed(s) BB Aggarwal, AB Kunnumakkara. World Scientific Publishing Co., Inc. Hackensack, 257-280, 2009.
5. Kaseb A, Thomas M. Chemotherapy and Novel Therapies. In: Hepatocellular Carcinoma: A Practical Approach. Ed(s) Bolini L, Reddy K, Al Knawy B. Informa Health Care Publishing Co., Inc. United Kingdom, 2008.
6. Azmi AS, Mohammad M, Kaseb A, Sarkar F, Mohammad RM. Utility of Animal Models in Pancreatic Cancer Research. In: Pancreatic Cancer. Chapter 34. Springer: New York, NY, 577-599, 2008.
7. Kaseb A, Tejwani S. Biological Response Modifiers in Cancer Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier, 2006.
8. Kaseb A, Tejwani S. Cancer Gene Therapy. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier, 2006.
9. Kaseb A, Tejwani S. Vaccines in Medical Oncology. In: Contemporary Perspectives on Clinical Pharmacotherapeutics. Ed(s) Kohli K. Elsevier Publishing Co., Inc., 2006.

Letters to the Editor

1. Kaseb AO, Morris JS, Hassan MM, Abbruzzese JL. Reply to A. Goyal et al. J Clin Oncol 30(24):1019-1020, 2/2012.

Last updated: 7/2/2015